A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.
Non-Squamous Non-Small Cell Lung Cancer
DRUG: Erlotinib
Survival Rate at Month 6, Month 6|Survival Rate at Month 12, Month 12|Progression Free Survival (PFS) at Month 6, PFS is defined as the time from inclusion in the study to the disease progression or death whichever occurs first. Disease progression was determined according to local treatment guidelines., From inclusion up to disease progression or death whichever occurs first (up to 6 months)|Progression Free Survival (PFS) at Month 12, PFS is defined as the time from inclusion in the study to the disease progression or death whichever occurs first. Disease progression was determined according to local treatment guidelines., From inclusion up to disease progression or death whichever occurs first (up to 12 months)
Overall Survival (OS), OS is defined as time from first administration of study drug until death from any cause., Up to 12 months|Percentage of Participants With Adverse Events (AEs), An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product., Up to 12 months|Overall Survival According to Prior Chemotherapy Treatment., Prior chemotherapy treatment is presented as reported by the investigators., Up to 12 months
This study will evaluate the survival of non-small cell lung cancer (wild-type EGFR) participants treated with Tarceva after at least one failed chemotherapy treatment, and the impact of prior chemotherapy treatments.